{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:22:26Z","timestamp":1790544146156,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"NWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jclinepi.2024.111479","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T02:53:05Z","timestamp":1721703185000},"page":"111479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-7898","authenticated-orcid":false,"given":"Merle-Marie","family":"Pittelkow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-090X","authenticated-orcid":false,"given":"Maximilian","family":"Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-4873","authenticated-orcid":false,"given":"Ymkje Anna","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-1432","authenticated-orcid":false,"given":"Lars G.","family":"Hemkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9568-8164","authenticated-orcid":false,"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-992X","authenticated-orcid":false,"given":"Rob R.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5030-4091","authenticated-orcid":false,"given":"Don","family":"van Ravenzwaaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2024.111479_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdt512","article-title":"How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers\u2019 views","volume":"25","author":"Tafuri","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jclinepi.2024.111479_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.24406","article-title":"Clinical trial evidence supporting US Food and drug administration approval of novel cancer therapies between 2000 and 2016","volume":"3","author":"Ladanie","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jclinepi.2024.111479_bib3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111479_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines","volume":"3","author":"Salas-Vega","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jclinepi.2024.111479_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.healthpol.2019.06.002","article-title":"Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs","volume":"123","author":"Vokinger","year":"2019","journal-title":"Health Policy"},{"key":"10.1016\/j.jclinepi.2024.111479_bib6","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and drug administration approval and indication extension of new cancer drugs, 2003-2021","volume":"40","author":"Michaeli","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2024.111479_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US Food and drug administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jclinepi.2024.111479_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jclinepi.2024.111479_bib11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.molonc.2014.10.003","article-title":"Assessment of benefits and risks in development of targeted therapies for cancer \u2014 the view of regulatory authorities","volume":"9","author":"Pignatti","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jclinepi.2024.111479_bib12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jclinepi.2024.111479_bib13","first-page":"1","article-title":"Informed bayesian T-tests","volume":"74","author":"Gronau","year":"2019","journal-title":"Am Stat"},{"key":"10.1016\/j.jclinepi.2024.111479_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3758\/PBR.16.2.225","article-title":"Bayesian t tests for accepting and rejecting the null hypothesis","volume":"16","author":"Rouder","year":"2009","journal-title":"Psychon Bull Rev"},{"key":"10.1016\/j.jclinepi.2024.111479_bib15","series-title":"Theory of probability","author":"Jeffreys","year":"1961"},{"key":"10.1016\/j.jclinepi.2024.111479_bib16","series-title":"Bayesian cognitive modeling: A practical course","author":"Lee","year":"2014"},{"key":"10.1016\/j.jclinepi.2024.111479_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-018-2877-z","article-title":"The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: rationale and design of the database and the collection of evidence available at approval of novel drugs","volume":"19","author":"Ladanie","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2024.111479_bib18","article-title":"How to use FDA drug approval documents for evidence syntheses","volume":"362","author":"Ladanie","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111479_bib19","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.jclinepi.2024.111479_bib20","author":"Linde"},{"key":"10.1016\/j.jclinepi.2024.111479_bib21","author":"Morey"},{"key":"10.1016\/j.jclinepi.2024.111479_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3758\/s13428-016-0739-8","article-title":"Default \u201cgunel and dickey\u201d Bayes factors for contingency tables","volume":"49","author":"Jamil","year":"2017","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.jclinepi.2024.111479_bib23","author":"Heck"},{"key":"10.1016\/j.jclinepi.2024.111479_bib24","article-title":"A primer on bayesian model-averaged meta-analysis","volume":"4","author":"Gronau","year":"2021","journal-title":"Adv Methods Pract Psychol Sci"},{"key":"10.1016\/j.jclinepi.2024.111479_bib25","series-title":"Accelerated Approval","year":"2023"},{"key":"10.1016\/j.jclinepi.2024.111479_bib26","series-title":"New FDA Reform Legislation: Congress Gifts a \u201cFDORA\u201d for the Holidays","year":"2023"},{"key":"10.1016\/j.jclinepi.2024.111479_bib27","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111479_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1365-2125.2001.01397-3.x","article-title":"Points to consider on switching between superiority and non-inferiority","volume":"52","year":"2001","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543562400235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543562400235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:56:22Z","timestamp":1730976982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089543562400235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"alternative-id":["S089543562400235X"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111479","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.30.23292074","asserted-by":"object"}]},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111479"}}